Chemokines and Chemokine Receptors in Infectious Disease

Current Topics in Membranes

Volumn 55, Issue , 2005, Pages 289-329

  Cortez, Karoll J ^a   Jackson, Julia O ^b   Kottilil, Shyam ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645894695     PISSN: 10635823     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1063-5823(04)55011-1     Document Type: Review

References (138)

1. Aarons E.J., Beddows S., Willingham T., Wu L., and Koup R.A. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287 (2001) 382-390
2. Achim C.L., and Wiley C.A. Inflammation in AIDS and the role of the macrophage in brain pathology. Curr. Opin. Neurol. 9 (1996) 221-225
3. Ahuja S.K., and Murphy P.M. Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J. Biol. Chem. 268 (1993) 20691-20694
4. Alfano M., Schmidtmayerova H., Amella C.A., Pushkarsky T., and Bukrinsky M. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J. Exp. Med. 190 (1999) 597-605
5. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
6. Arenzana-Seisdedos F., Virelizier J.L., Rousset D., Clark-Lewis I., Loetscher P., Moser B., and Baggiolini M. HIV blocked by chemokine antagonist. Nature 383 (1996) 400
7. Arthos J., Rubbert A., Rabin R.L., Cicala C., Machado E., Wildt K., Hanbach M., Steenbeke T.D., Swofford R., Farber J.M., and Fauci A.S. CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. J. Virol. 74 (2000) 6418-6424
8. Arya S.K., Ginsberg C.C., Davis-Warren A., and D'Costa J. In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. J. Hum. Virol. 2 (1999) 133-138
9. Asensio V.C., Kincaid C., and Campbell I.L. Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J. Neurovirol. 5 (1999) 65-75
10. Atchison R.E., Gosling J., Monteclaro F.S., Franci C., Digilio L., Charo I.F., and Goldsmith M.A. Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 274 (1996) 1924-1926
11. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96 (1999) 5698-5703
12. Baggiolini M., Dewald B., and Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55 (1994) 97-179
13. Baggiolini M., Dewald B., and Moser B. Human chemokines: An update. Annu. Rev. Immunol. 15 (1997) 675-705
14. Bai X., Chen J.D., Yang A.G., Torti F., and Chen S.Y. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene. Ther. 5 (1998) 984-994
15. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
16. Bernasconi S., Cinque P., Peri G., Sozzani S., Crociati A., Torri W., Vicenzi E., Vago L., Lazzarin A., Poli G., and Mantovani A. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J. Infect. Dis. 174 (1996) 1098-1101
17. Bhopale G.M. Pathogenesis of toxoplasmosis. Comp. Immunol. Microbiol. Infect. Dis. 26 (2003) 213-222
18. Biti R., Ffrench R., Young J., Bennetts B., Stewart G., and Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat. Med. 3 (1997) 252-253
19. Bodaghi B., Jones T.R., Zipeto D., Vita C., Sun L., Laurent L., Arenzana-Seisdedos F., Virelizier J.L., and Michelson S. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med. 188 (1998) 855-866
20. Boshoff C., Endo Y., Collins P.D., Takeuchi Y., Reeves J.D., Schweickart V.L., Siani M.A., Sasaki T., Williams T.J., Gray P.W., Moore P.S., Chang Y., and Weiss R.A. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278 (1997) 290-294
21. Bukrinskaya A., Brichacek B., Mann A., and Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J. Exp. Med. 188 (1998) 2113-2125
22. Chen J.D., Bai X., Yang A.G., Cong Y., and Chen S.Y. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat. Med. 3 (1997) 1110-1116
23. Cheng-Mayer C., Seto D., Tateno M., and Levy J.A. Biologic features of HIV-1 that correlate with virulence in the host. Science 240 (1988) 80-82
24. Cicala C., Arthos J., Selig S.M., Dennis Jr. G., Hosack D.A., Van Ryk D., Spangler M.L., Steenbeke T.D., Khazanie P., Gupta N., Yang J., Daucher M., Lempicki R.A., and Fauci A.S. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc. Natl. Acad. Sci. USA 99 (2002) 9380-9385
25. Cocchi F., DeVico A.L., Garzino-Demo A., Cara A., Gallo R.C., and Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2 (1996) 1244-1247
26. Craigen J.L., Yong K.L., Jordan N.J., MacCormac L.P., Westwick J., Akbar A.N., and Grundy J.E. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 92 (1997) 138-145
27. Daelemans D., Schols D., Witvrouw M., Pannecouque C., Hatse S., van Dooren S., Hamy F., Klimkait T., de Clercq E., and VanDamme A.M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol. 57 (2000) 116-124
28. Damon I., Murphy P.M., and Moss B. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Natl. Acad. Sci. USA 95 (1998) 6403-6407
29. Del Rio L., Bennouna S., Salinas J., and Denkers E.Y. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J. Immunol. 167 (2001) 6503-6509
30. Demerest J., Sparks A.K., Shachoy-Clark S., Schell K., O'Mara S.F., Shibayama S., and Piscitelli S. Single and dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 antagonist, in healthy subjects. "11th Conference on Retroviruses and Opportunistic Infections," (2004) Abstract #139, San Francisco.
31. Dolei A., Biolchini A., Serra C., Curreli S., Gomes E., and Dianzani F. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines. AIDS 12 (1998) 183-190
32. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., Doms R.W., and O'Brien W.A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186 (1997) 1395-1400
33. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., and Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA 97 (2000) 5639-5644
34. Easterbrook P.J., Rostron T., Ives N., Troop M., Gazzard B.G., and Rowland-Jones S.L. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J. Infect. Dis. 180 (1999) 1096-1105
35. Eron J.J., and Hogan C.M. Entry and fusion inhibitors: An update. The PRN Notebook 7 (2002) 16-22
36. Faure S., Meyer L., Costagliola D., Vaneensberghe C., Genin E., Autran B., Delfraissy J.F., McDermott D.H., Murphy P.M., Debre P., Theodorou I., and Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 (2000) 2274-2277
37. Fenard D., Lambeau G., Maurin T., Lefebvre J.C., and Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. 60 (2001) 341-347
38. Gao J.L., and Murphy P.M. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J. Biol. Chem. 269 (1994) 28539-28542
39. Garden G.A. Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 40 (2002) 240-251
40. Gerard C., and Gerard N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12 (1994) 775-808
41. Goldman D.W., and Goetzl E.J. Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. J. Immunol. 129 (1982) 1600-1604
42. Gu L., Tseng S., Horner R.M., Tam C., Loda M., and Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404 (2000) 407-411
43. Hajeer A.H., al Sharif F., and Ollier W.E. A polymorphism at position -403 in the human RANTES promoter. Eur. J. Immunogenet. 26 (1999) 375-376
44. Hanahan D.J. Platelet activating factor: A biologically active phosphoglyceride. Annu. Rev. Biochem. 55 (1986) 483-509
45. He J., Chen Y., Farzan M., Choe H., Ohagen A., Gartner S., Busciglio J., Yang X., Hofmann W., Newman W., Mackay C.R., Sodroski J., and Gabuzda D. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385 (1997) 645-649
46. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., Bridger G., and Henson G.W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents. Chemother. 44 (2000) 1667-1673
47. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., and Miller L.H. A receptor for the malarial parasite Plasmodium vivax: The erythrocyte chemokine receptor. Science 261 (1993) 1182-1184
48. Howard O.M., Korte T., Tarasova N.I., Grimm M., Turpin J.A., Rice W.G., Michejda C.J., Blumenthal R., and Oppenheim J.J. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J. Leukoc. Biol. 64 (1998) 6-13
49. Hu Z., Yang Q., Bo X., and Li J. Herpes simplex encephalitis. Lancet 362 (2003) 280
50. Huffnagle G.B., and McNeil L.K. Dissemination of C. neoformans to the central nervous system: Role of chemokines, Th1 immunity and leukocyte recruitment. J. Neurovirol. 5 (1999) 76-81
51. Huffnagle G.B., McNeil L.K., McDonald R.A., Murphy J.W., Toews G.B., Maeda N., and Kuziel W.A. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163 (1999) 4642-4646
52. Hughes P.M., Botham M.S., Frentzel S., Mir A., and Perry V.H. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37 (2002) 314-327
53. Kabat D., Kozak S.L., Wehrly K., and Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 68 (1994) 2570-2567.
54. Khabar K.S., Al-Zoghaibi F., Al-Ahdal M.N., Murayama T., Dhalla M., Mukaida N., Taha M., Al-Sedairy S.T., Siddiqui Y., Kessie G., and Matsushima K. The alpha chemokine, interleukin-8, inhibits the antiviral action of interferon alpha. J. Exp. Med. 186 (1997) 1077-1085
55. Khan I.A., MacLean J.A., Lee F.S., Casciotti L., DeHaan E., Schwartzman J.D., and Luster A.D. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12 (2000) 483-494
56. Khan I.A., Murphy P.M., Casciotti L., Schwartzman J.D., Collins J., Gao J.L., and Yeaman G.R. Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection. J. Immunol. 166 (2001) 1930-1937
57. Kielian T. Microglia and chemokines in infectious diseases of the nervous system: Views and reviews. Front. Biosci. 9 (2004) 732-750
58. Kinter A., Arthos J., Cicala C., and Fauci A.S. Chemokines, cytokines and HIV: A complex network of interactions that influence HIV pathogenesis. Immunol. Rev. 177 (2000) 88-98
59. Kinter A., Catanzaro A., Monaco J., Ruiz M., Justement J., Moir S., Arthos J., Oliva A., Ehler L., Mizell S., Jackson R., Ostrowski M., Hoxie J., Offord R., and Fauci A.S. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction. Proc. Natl. Acad. Sci. USA 95 (1998) 11880-11885
60. Kinter A.L., Ostrowski M., Goletti D., Oliva A., Weissman D., Gantt K., Hardy E., Jackson R., Ehler L., and Fauci A.S. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. USA 93 (1996) 14076-14081
61. Kitai R., Zhao M.L., Zhang N., Hua L.L., and Lee S.C. Role of MIP-1beta and RANTES in HIV-1 infection of microglia: Inhibition of infection and induction by IFNbeta. J. Neuroimmunol. 110 (2000) 230-239
62. Kledal T.N., Rosenkilde M.M., Coulin F., Simmons G., Johnsen A.H., Alouani S., Power C.A., Luttichau H.R., Gerstoft J., Clapham P.R., Clark-Lewis I., Wells T.N., and Schwartz T.W. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277 (1997) 1656-1659
63. Kostrikis L.G., Neumann A.U., Thomson B., Korber B.T., McHardy P., Karanicolas R., Deutsch L., Huang Y., Lew J.F., McIntosh K., Pollack H., Borkowsky W., Spiegel H.M., Palumbo P., Oleske J., Bardeguez A., Luzuriaga K., Sullivan J., Wolinsky S.M., Koup R.A., Ho D.D., and Moore J.P. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J. Virol. 73 (1999) 10264-10271
64. Kottilil S., Shin K., Planta M., McLaughlin M., Hallahan C.W., Ghany M., Chun T.W., Sneller M.C., and Fauci A.S. Expression of chemokine and inhibitory receptors on natural killer cells: Effect of immune activation and HIV viremia. J. Infect. Dis. 189 (2004) 1193-1198
65. Kure K., Weidenheim K.M., Lyman W.D., and Dickson D.W. Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. Acta. Neuropathol. (Berl) 80 (1990) 393-400
66. Kusunoki A., Wada A., Kurosaki N., Kimura T., Takai K., Yamamoto N., and Takaku H. Antisense oligodeoxynucleotide complementary to CXCR4 mRNA block replication of HIV-1 in COS cells. Nucleosides. Nucleotides. 18 (1999) 1705-1708
67. Lahrtz F., Piali L., Nadal D., Pfister H.W., Spanaus K.S., Baggiolini M., and Fontana A. Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1. Eur. J. Immunol. 27 (1997) 2484-2489
68. Lahrtz F., Piali L., Spanaus K.S., Seebach J., and Fontana A. Chemokines and chemotaxis of leukocytes in infectious meningitis. J. Neuroimmunol. 85 (1998) 33-43
69. Lalani A.S., Masters J., Zeng W., Barrett J., Pannu R., Everett H., Arendt C.W., and McFadden G. Use of chemokine receptors by poxviruses. Science 286 (1999) 1968-1971
70. Lane B.R., Markovitz D.M., Woodford N.L., Rochford R., Strieter R.M., and Coffey M.J. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J. Immunol. 163 (1999) 3653-3661
71. Lapham C.K., Ouyang J., Chandrasekhar B., Nguyen N.Y., Dimitrov D.S., and Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274 (1996) 602-605
72. Lipton S.A., Yeh M., and Dreyer E.B. Update on current models of HIV-related neuronal injury: Platelet-activating factor, arachidonic acid and nitric oxide. Adv. Neuroimmunol. 4 (1994) 181-188
73. Liu H., Chao D., Nakayama E.E., Taguchi H., Goto M., Xin X., Takamatsu J.K., Saito H., Ishikawa Y., Akaza T., Juji T., Takebe Y., Ohishi T., Fukutake K., Maruyama Y., Yashiki S., Sonoda S., Nakamura T., Nagai Y., Iwamoto A., and Shioda T. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA 96 (1999) 4581-4585
74. Lokensgard J.R., Hu S., Sheng W., vanOijen M., Cox D., Cheeran M.C., and Peterson P.K. Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J. Neurovirol. 7 (2001) 208-219
75. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., Miyakawa T., Aoki M., Fukushima D., and Mitsuya H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276 (2001) 35194-35200
76. Margolis L.B., Glushakova S., Grivel J.C., and Murphy P.M. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. J. Clin. Invest. 101 (1998) 1876-1880
77. Mariani R., Wong S., Mulder L.C., Wilkinson D.A., Reinhart A.L., LaRosa G., Nibbs R., O'Brien T.R., Michael N.L., Connor R.I., Macdonald M., Busch M., Koup R.A., and Landau N.R. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J. Virol. 73 (1999) 2450-2459
78. McDermott D.H., Beecroft M.J., Kleeberger C.A., Al-Sharif F.M., Ollier W.E., Zimmerman P.A., Boatin B.A., Leitman S.F., Detels R., Hajeer A.H., and Murphy P.M. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 14 (2000) 2671-2678
79. McDermott D.H., Colla J.S., Kleeberger C.A., Plankey M., Rosenberg P.S., Smith E.D., Zimmerman P.A., Combadiere C., Leitman S.F., Kaslow R.A., Goedert J.J., Berger E.A., O'Brien T.R., and Murphy P.M. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 290 (2000) 2031
80. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., and Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352 (1998) 866-870
81. McKnight A., Wilkinson D., Simmons G., Talbot S., Picard L., Ahuja M., Marsh M., Hoxie J.A., and Clapham P.R. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71 (1997) 1692-1696
82. Mebatsion T., Finke S., Weiland F., and Conzelmann K.K. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90 (1997) 841-847
83. Mellado M., Rodriguez-Frade J.M., Vila-Coro A.J., de Ana A.M., and Martinez A.C. Chemokine control of HIV-1 infection. Nature 400 (1999) 723-724
84. Miller L.H., Mason S.J., Clyde D.F., and McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295 (1976) 302-304
85. Moriuchi M., Moriuchi H., Turner W., and Fauci A.S. Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J. Clin. Invest. 102 (1998) 1540-1550
86. Mosier D.E., Picchio G.R., Gulizia R.J., Sabbe R., Poignard P., Picard L., Offord R.E., Thompson D.A., and Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73 (1999) 3544-3550
87. Murakami T., Zhang T.Y., Koyanagi Y., Tanaka Y., Kim J., Suzuki Y., Minoguchi S., Tamamura H., Waki M., Matsumoto A., Fujii N., Shida H., Hoxie J.A., Peiper S.C., and Yamamoto N. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J. Virol. 73 (1999) 7489-7496
88. Murayama T., Kuno K., Jisaki F., Obuchi M., Sakamuro D., Furukawa T., Mukaida N., and Matsushima K. Enhancement human cytomegalovirus replication in a human lung fibroblast cell line by interleukin-8. J. Virol. 68 (1994) 7582-7585
89. Murphy P.M. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12 (1994) 593-633
90. Murphy P.M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2 (2001) 116-122
91. Nakajima H., Kobayashi M., Pollard R.B., and Suzuki F. Monocyte chemoattractant protein-1 enhances HSV-induced encephalomyelitis by stimulating Th2 responses. J. Leukoc. Biol. 70 (2001) 374-380
92. Nau R., and Bruck W. Neuronal injury in bacterial meningitis: Mechanisms and implications for therapy. Trends. Neurosci. 25 (2002) 38-45
93. Nickel R.G., Casolaro V., Wahn U., Beyer K., Barnes K.C., Plunkett B.S., Freidhoff L.R., Sengler C., Plitt J.R., Schleimer R.P., Caraballo L., Naidu R.P., Levett P.N., Beaty T.H., and Huang S.K. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J. Immunol. 164 (2000) 1612-1616
94. O'Brien T.R., McDermott D.H., Ioannidis J.P., Carrington M., Murphy P.M., Havlir D.V., and Richman D.D. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14 (2000) 821-826
95. Ostrowski M.A., Justement S.J., Catanzaro A., Hallahan C.A., Ehler L.A., Mizell S.B., Kumar P.N., Mican J.A., Chun T.W., and Fauci A.S. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J. Immunol. 161 (1998) 3195-3201
96. Ostrowski M.A., Krakauer D.C., Li Y., Justement S.J., Learn G., Ehler L.A., Stanley S.K., Nowak M., and Fauci A.S. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J. Virol. 72 (1998) 7772-7784
97. Patterson C.E., Daley J.K., Echols L.A., Lane T.E., and Rall G.F. Measles virus infection induces chemokine synthesis by neurons. J. Immunol. 171 (2003) 3102-3109
98. Penfold M.E., Dairaghi D.J., Duke G.M., Saederup N., Mocarski E.S., Kemble G.W., and Schall T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA 96 (1999) 9839-9844
99. Pleskoff O., Treboute C., Brelot A., Heveker N., Seman M., and Alizon M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276 (1997) 1874-1878
100. Proudfoot A.E., Buser R., Borlat F., Alouani S., Soler D., Offord R.E., Schroder J.M., Power C.A., and Wells T.N. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. 274 (1999) 32478-32485
101. Reinhart T.A. Chemokine induction by HIV-1: Recruitment to the cause. Trends. Immunol. 24 (2003) 351-353
102. Rodrigues M.L., Alviano C.S., and Travassos L.R. Pathogenicity of Cryptococcus neoformans: Virulence factors and immunological mechanisms. Microbes. Infect. 1 (1999) 293-301
103. Rodriguez-Frade J.M., Vila-Coro A.J., de Ana A.M., Albar J.P., Martinez A.C., and Mellado M. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc. Natl. Acad. Sci. USA 96 (1999) 3628-3633
104. Rosler A., Pohl M., Braune H.J., Oertel W.H., Gemsa D., and Sprenger H. Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. J. Neurol. Sci. 157 (1998) 82-89
105. Sakaida H., Hori T., Yonezawa A., Sato A., Isaka Y., Yoshie O., Hattori T., and Uchiyama T. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J. Virol. 72 (1998) 9763-9770
106. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
107. Sanders V.J., Pittman C.A., White M.G., Wang G., Wiley C.A., and Achim C.L. Chemokines and receptors in HIV encephalitis. AIDS 12 (1998) 1021-1026
108. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., Malnati M.S., Plebani A., Siccardi A.G., Littman D.R., Fenyo E.M., and Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3 (1997) 1259-1265
109. Schiffmann E., Showell H.V., Corcoran B.A., Ward P.A., Smith E., and Becker E.L. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J. Immunol. 114 (1975) 1831-1837
110. Schnell M.J., Johnson J.E., Buonocore L., and Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90 (1997) 849-857
111. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., Van Damme J., and De Clercq E. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral. Res. 39 (1998) 175-187
112. Schols D., Vermeire K., Hatse S., Princen K., De Clerq E., Calandra G., Fricker S., Nelson K., Labrecque J., Bogucki D., Zhou Y., Skerlj R., and Bridger G. In vitro anti-HIV activity profile of AMD887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070. "11th Conference on Retroviruses and Opportunistic Infections," (2004) Abstract #539, San Francisco.
113. Schuitemaker H., Kootstra N.A., de Goede R.E., de Wolf F., Miedema F., and Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65 (1991) 356-363
114. Schurman D., Nougarede R.R., Reynes J., Fatkenheur G., Raffi F., Michelet C., Tarral A., Hoffman C., Kiunke J., Spenger H., banLier J., Sansome S., Jackson M., and Laughlin M. SCH-D: Antiviral activity of a CCR5 receptor antagonist. "11th Conference on Retroviruses and Opportunistic Infections," (2004) Abstract #140LB, San Francisco.
115. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N., and Proudfoot A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276 (1997) 276-279
116. Steinberger P., Andris-Widhopf J., Buhler B., Torbett B.E., and Barbas III C.F. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 97 (2000) 805-810
117. Strack A., Schluter D., Asensio V.C., Campbell I.L., and Deckert M. Regulation of the kinetics of intracerebral chemokine gene expression in murine Toxoplasma encephalitis: Impact of host genetic factors. Glia 40 (2002) 372-377
118. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., and Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 12718-12723
119. Swingler S., Mann A., Jacque J., Brichacek B., Sasseville V.G., Williams K., Lackner A.A., Janoff E.N., Wang R., Fisher D., and Stevenson M. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 5 (1999) 997-1003
120. Tamamura H., Xu Y., Hattori T., Zhang X., Arakaki R., Kanbara K., Omagari A., Otaka A., Ibuka T., Yamamoto N., Nakashima H., and Fujii N. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 253 (1998) 877-882
121. Tournamille C., Colin Y., Cartron J.P., and Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat. Genet. 10 (1995) 224-228
122. Townsend G.C., and Scheld W.M. Infections of the central nervous system. Adv. Intern. Med. 43 (1998) 403-447
123. Tremblay C.L., Giguel F., Kollmann C., Guan Y., Chou T.C., Baroudy B.M., and Hirsch M.S. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46 (2002) 1336-1339
124. Tremblay C.L., Kollmann C., Giguel F., Chou T.C., and Hirsch M.S. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune. Defic. Syndr. 25 (2000) 99-102
125. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 (2001) 579-588
126. Valdez H., Purvis S.F., Lederman M.M., Fillingame M., and Zimmerman P.A. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA 282 (1999) 734
127. Verani A., Scarlatti G., Comar M., Tresoldi E., Polo S., Giacca M., Lusso P., Siccardi A.G., and Vercelli D. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 185 (1997) 805-816
128. Watson S., and Arkinstall S. "The G-protein linked receptor." (1994), Academic Press, London
129. Weiss J.M., Nath A., Major E.O., and Berman J.W. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J. Immunol. 163 (1999) 2953-2959
130. Weissman D., Rabin R.L., Arthos J., Rubbert A., Dybul M., Swofford R., Venkatesan S., Farber J.M., and Fauci A.S. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389 (1997) 981-985
131. Westby M.W.J., Huang W., James I., Abel S., Petropoulos C., Perros M., and van der Ryst E. Reversible predominance of CXCR4 utilizing variants in a non-responsive dual-tropic Patient Receiving the CCR5 Antagonist UK-427857. "11th Conference on Retroviruses and Opportunistic Infections," (2004) Abstract #538, San Francisco.
132. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., Chen H., Humblias J., Samson M., Parmentier M., Moore J.P., and Mackay C.R. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 (1997) 1373-1381
133. Xiao X., Wu L., Stantchev T.S., Feng Y.R., Ugolini S., Chen H., Shen Z., Riley J.L., Broder C.C., Sattentau Q.J., and Dimitrov D.S. Constitutive cell surface association between CD4 and CCR5. Proc. Natl. Acad. Sci. USA 96 (1999) 7496-7501
134. Yang T.Y., Chen S.C., Leach M.W., Manfra D., Homey B., Wiekowski M., Sullivan L., Jenh C.H., Narula S.K., Chensue S.W., and Lira S.A. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191 (2000) 445-454
135. Yang X.D., Corvalan J.R., Wang P., Roy C.M., and Davis C.G. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. 66 (1999) 401-410
136. Zimmerman P.A., Buckler-White A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C., Weissman D., Cohen O., Rubbert A., Lam G., Vaccarezza M., Kennedy P.E., Kumaraswami V., Giorgi J.V., Detels R., Hunter J., Chopek M., Berger E.A., Fauci A.S., Nutman T.B., and Murphy P.M. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3 (1997) 23-36
137. Zou P., Isegawa Y., Nakano K., Haque M., Horiguchi Y., and Yamanishi K. Human herpesvirus 6 open reading frame U83 encodes a functional chemokine. J. Virol. 73 (1999) 5926-5933
138. Zwijnenburg P.J., van der Poll T., Florquin S., van Deventer S.J., Roord J.J., and van Furth A.M. Experimental pneumococcal meningitis in mice: A model of intranasal infection. J. Infect. Dis. 183 (2001) 1143-1146